The PROPER study: interim analysis of a Pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn's disease

被引：0
|
作者：
Dignass, A. U. [1 ]
Gisbert, J. P. [2 ]
Bossa, F. [3 ]
Freudensprung, U. [4 ]
Addison, J. [5 ]
机构：
[1] Goethe Univ, Dept Med, Agaples Markus Hospital, Frankfurt, Germany
[2] Univ Autonoma Madrid, Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IIS IP,Gastroenter, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
[3] Fdn Casa Sollievo della Sofferenza, IRCCS San Giovanni Rotondo, Div Gastroenterol, Puglia, Italy
[4] Biogen Int GmbH, Med Data Sci & Analyt MDSA Biosimilars, Baar, Switzerland
[5] Biogen Biosimilars Unit, Med, Baar, Switzerland
来源：
JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P434
引用
收藏
页码：I418 / I418
页数：1
相关论文
共 50 条
  • [21] Evaluation of the safety and effectiveness after switch from adalimumab originator to biosimilar SB5 in patients with inflammatory bowel disease in a real-life setting
    Deprez, N.
    De Somer, T.
    Baert, D.
    Deceuninck, M.
    Huys, I.
    Mattens, V.
    Sterckx, A.
    Vanderstraeten, E.
    Vandervoort, J.
    Van Heddegem, N.
    Dewint, P.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2022, 85 (04) : 557 - 564
  • [22] Real-World Efficacy And Safety Of Ustekinumab And Adalimumab In Patients With Crohn's Disease: Propensity Matched Analysis
    Shin, Y.
    Hong, S. N.
    Kim, E. R.
    Chang, D. K.
    Kim, Y. H.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 842 - 842
  • [23] Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study
    Bouguen, Guillaume
    Gossec, Laure
    Abitbol, Vered
    Senbel, Eric
    Bonnaud, Guillaume
    Roblin, Xavier
    Bouhnik, Yoram
    Nancey, Stephane
    Mathieu, Nicolas
    Filippi, Jerome
    Vuitton, Lucine
    Nahon, Stephane
    Dellal, Azeddine
    Denis, Alice
    Foulley, Lucile
    Habauzit, Caroline
    Benkhalifa, Salim
    Marotte, Hubert
    BIODRUGS, 2024, 38 (06) : 867 - 878
  • [24] Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study
    Wang, Fang
    Li, Xiaofei
    Shi, Yanting
    Zhou, He
    Yang, Gang
    Li, Ruixia
    Wu, Tong
    Liang, Jie
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [25] Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study
    Fautrel, Bruno
    Bouhnik, Yoram
    Salliot, Carine
    Carbonnel, Franck
    Fumery, Mathurin
    Bernardeau, Christophe
    Maugars, Yves
    Flamant, Mathurin
    Coury, Fabienne
    Braithwaite, Ben
    Hateb, Salima
    Addison, Janet
    DRUGS-REAL WORLD OUTCOMES, 2024, 11 (04) : 573 - 591
  • [26] Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study
    Sieborg, Johan
    Maul, Julia-Tatjana
    Wu, Jashin J.
    Loft, Nikolai Nguyen
    Skov, Lone
    Bryld, Lars Erik
    Rasmussen, Mads Kirchheine
    Dam, Tomas Norman
    Bertelsen, Trine
    Ajgeiy, Kawa Khaled
    Thomsen, Simon Francis
    Thyssen, Jacob P.
    Egeberg, Alexander
    Thein, David
    ACTA DERMATO-VENEREOLOGICA, 2025, 105
  • [27] Real-world persistence of ustekinumab vs infliximab and adalimumab in patients with Crohn's disease: A meta-analysis
    Yiu, T. H.
    Ko, Y.
    Pudipeddi, A.
    Chetwood, J.
    Leong, R.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 195 - 195
  • [28] IMPACT OF ADALIMUMAB SERUM CONCENTRATION ON EFFICACY AND ASSOCIATION BETWEEN ANTI-DRUG ANTIBODIES AND SERUM CONCENTRATION: 24 WEEK RESULTS FROM A PHASE III STUDY COMPARING SB5 (AN ADALIMUMAB BIOSIMILAR) WITH REFERENCE ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Kay, J.
    Weinblatt, M.
    Keystone, E.
    Genovese, M.
    Ghil, J.
    Cheong, S. Y.
    Hong, E. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 136 - 136
  • [29] Acceptance of switch, patient satisfaction and adverse events after switch from adalimumab originator to biosimilar SB5 in patients with Inflammatory Bowel Disease in a real-life setting
    De Somer, T.
    Deprez, N.
    Baert, D.
    Deceuninck, M.
    Huys, I.
    Mattens, V.
    Sterckx, A.
    Vanden Branden, S.
    Vanderstraeten, E.
    Vandervoort, J.
    Van Heddegem, N.
    Dewint, P.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S406 - S406
  • [30] Real-world effectiveness & safety of fremanezumab in migraine: 3rd interim analysis of the pan-European PEARL study
    Ashina, M.
    Mitsikostas, D.
    Amin, F.
    Kokturk, P.
    Schankin, C.
    Sahin, G.
    Pozo-Rosich, P.
    Dorman, P.
    Nezadal, T.
    Poole, A.
    Martins, I.
    Sumelahti, M.
    Campos, V. Ramirez
    Ning, X.
    Lyras, L.
    Tassorelli, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 149 - 150
12345